NCT06553040

Brief Summary

The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2017

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

August 10, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 14, 2024

Completed
Last Updated

August 14, 2024

Status Verified

August 1, 2024

Enrollment Period

4.9 years

First QC Date

August 10, 2024

Last Update Submit

August 10, 2024

Conditions

Pancreatic NeoplasmsPancreas Cancer

Keywords

Pancreatic adenocanceralbuminhemoglobinlymphocyteplatelet

Outcome Measures

Primary Outcomes (4)

  • Disease-Free Survival Times

    4 Years

  • HALP Score

    Hemoglobin x Albumin x Lymphocyte / Platelet

    4 Years

  • Overall Survival Time

    4 Years

  • LCR Score

    Lymphocyte / CRP

    4 Years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study included 87 patients who underwent either pancreaticoduodenectomy (Whipple or total pancreatectomy) operations for pancreatic adenocarcinoma in the General Surgery Clinic of Ege University Hospital between January 2017 and December 2021.

You may qualify if:

  • Whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma

You may not qualify if:

  • Patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist

Study Record Dates

First Submitted

August 10, 2024

First Posted

August 14, 2024

Study Start

January 1, 2017

Primary Completion

December 1, 2021

Study Completion

January 1, 2023

Last Updated

August 14, 2024

Record last verified: 2024-08